Methallylescaline

Methallylescaline (MAL; 2-[3,5-dimethoxy-4-(2-methylprop-2-enoxy)phenyl]ethanamine) is a synthetic psychedelic phenethylamine of the scaline structural class, first synthesized and self-administered by Alexander Shulgin in the early 1980s and formally documented in entry number 99 of his 1991 reference work PiHKAL (Phenethylamines I Have Known and Loved). The compound is the 4-methallyloxy homolog of mescaline (3,4,5-trimethoxyphenethylamine), differing from the parent alkaloid by replacement of the 4-methoxy group with a 2-methylprop-2-enyloxy (methallyloxy) substituent. This structural modification increases lipophilicity, enhances blood-brain barrier permeability, and produces a compound with approximately six-fold greater potency than mescaline, an oral dose range of 40 to 65 milligrams (compared to 200 to 400 milligrams for mescaline), and a duration of action of 12 to 16 hours.

The principal molecular target of methallylescaline is the serotonin 5-hydroxytryptamine type 2A (5-HT2A) receptor, at which the compound acts as an agonist to produce the characteristic psychedelic phenomenology of the phenethylamine class: visual distortion, perceptual intensification, synesthesia, and altered cognition. The compound also binds the 5-HT2C receptor and, at higher concentrations, the 5-HT1A receptor (Ki in the low micromolar range). The receptor interaction profile was formally characterized in the Kolaczynska, Luethi, Trachsel, Hoener, and Liechti (2022) systematic study of 4-alkoxy-3,5-dimethoxyphenethylamines (mescaline derivatives) and related amphetamines, which established that scalines as a class bind 5-HT2A and 5-HT2C receptors with affinities up to 63-fold and 34-fold greater than mescaline, respectively. The study further demonstrated that extending and branching the 4-alkoxy substituent increased binding affinity and activation potency at the 5-HT2A receptor while producing variable effects at the 5-HT2B receptor, a finding with implications for both potency and cardiovascular safety assessment.

Pharmacokinetic data specific to methallylescaline in humans are absent from the peer-reviewed literature. Inferences drawn from mescaline pharmacokinetics (oral absorption with Tmax of approximately 2 hours, plasma half-life of approximately 3.5 hours, predominant elimination by oxidative deamination and renal excretion of unchanged drug) and from the structural properties of the methallyloxy substituent (increased lipophilicity, probable hepatic O-dealkylation to yield a demethylated phenolic metabolite) suggest that methallylescaline is rapidly absorbed, extensively distributed to central nervous system tissue, and eliminated over a time course consistent with its prolonged 12 to 16 hour subjective duration. The steep dose-response relationship reported by Shulgin, in which small increments in dose produce disproportionately large increases in effect intensity, is characteristic of agonists operating near the inflection point of a sigmoidal concentration-effect curve and may reflect cooperative receptor binding or threshold-dependent downstream signaling amplification.

Preclinical pharmacology data for methallylescaline are limited. The Halberstadt, Chatha, Chapman, and Brandt (2019) study of the mouse head-twitch response (a 5-HT2A receptor-mediated behavioral proxy for psychedelic potency) characterized several mescaline analogs in the scaline series and established the general principle that extension of the 4-alkoxy chain increases in vivo potency relative to mescaline. No clinical trials, controlled human pharmacology studies, or formal toxicology assessments of methallylescaline have been conducted. The compound has no approved medical indication in any jurisdiction.

This monograph documents the chemistry, synthesis, structural class, and nomenclature of methallylescaline; the receptor pharmacology as characterized in the Kolaczynska et al. (2022) systematic study; inferred pharmacokinetics based on the mescaline pharmacokinetic record and structural analogy; preclinical pharmacology from the scaline head-twitch response literature; the absence of clinical evidence; sourcing and quality verification considerations; reconstitution and handling; stack interaction considerations; adverse events and safety signal; and a comparative assessment of five structurally or mechanistically related phenethylamine psychedelics (mescaline, escaline, allylescaline, proscaline, and 3C-E) against methallylescaline on five competency standards.